- Published on: April 30, 2022
- 00:14
Havana, Apr 30 (Prensa Latina) The file containing the protocol to carry out the phase III clinical trial with the neuroprotective drug NeuroEPO in patients with ataxia, was presented for approval to the Cuban regulatory entity, they disclosed on Friday.
